title: Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
abstract: OBJECTIVE
  To determine if circadian timed (CT) chemotherapy results in improved response, progression-free survival (PFS), overall survival (OS), and lower toxicity, when compared with standard timed (ST) chemotherapy.
  
  
  METHODS
  Eligibility criteria were stage III, IV, or recurrent endometrial cancer with poor potential for cure by radiation therapy or surgery; measurable disease; and no prior chemotherapy. Therapy was randomized to schedules of ST doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2, or CT doxorubicin 60 mg/m2 at 6:00 am plus cisplatin 60 mg/m2 at 6:00 pm. Cycles were repeated every 3 weeks to a maximum of eight cycles.
  
  
  RESULTS
  The ST arm included 169 patients, and the CT arm included 173 patients. The objective response rate (complete responses plus partial responses) was 46% in the ST group compared with 49% in the CT group (P =.26, one tail). Median PFS and OS were 6.5 and 11.2 months, respectively, in the ST group; and 5.9 and 13.2 months, respectively, in the CT group (PFS: P =.31; OS: P =.21, one tail). Median total doses were 209 mg/m2 doxorubicin and 349 mg/m2 cisplatin in the ST group, versus 246 mg/m2 doxorubicin and 354 mg/m2 cisplatin in the CT group. Grade 3 or 4 leukopenia occurred in 73% of patients in the ST arm and in 63% of patients in the CT arm. There were eight treatment-related deaths.
  
  
  CONCLUSIONS
  In this trial, no significant benefit in terms of response rate, PFS or OS, or toxicity profile was observed with CT doxorubicin plus cisplatin in patients with advanced or recurrent endometrial carcinoma.
authors.affiliation: Division of Gynecologic Oncology, Magee Women's Hospital/University of Pittsburgh, Pittsburgh, PA, USA. hgallion@mail.magee.edu
authors.forename: Holly H
authors.initials: HH
authors.lastname: Gallion
authors.forename: Virginia L
authors.initials: VL
authors.lastname: Brunetto
authors.forename: Michael
authors.initials: M
authors.lastname: Cibull
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Lentz
authors.forename: Gary
authors.initials: G
authors.lastname: Reid
authors.forename: John T
authors.initials: JT
authors.lastname: Soper
authors.forename: Robert A
authors.initials: RA
authors.lastname: Burger
authors.forename: Willie
authors.initials: W
authors.lastname: Andersen
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis
chemical_list: D004317:Doxorubicin; D002945:Cisplatin